Andrulis Research Corporation

7315 Wisconsin Ave - Ste 650N
Bethesda, MD 20814
55 Employees

SBIR Award Summary

Total Number of Awards 9
Total Value of Awards $559K
First Award Date 01/01/83
Most Recent Award Date 05/10/90

Key Personnel

Last Name Name Awards Contact
Gill Devinder S Gill 2
Andrulis Peter J Andrulis 1
Schwartz Paul Schwartz 3
Biswas Clare J Biswas 1
Gill Devinder S Gill 2

9 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/10/90 - 03/31/91

The overall objective of this study is to provide a new drug delivery system and to enhance the solubility of existing compounds which exhibit excellent antitumor properties but are insoluble in water. Aqueous' solubility is essential for iv administration of antitumor drugs. Phase I research will solubilize diammineplatinumhydroxymalonate, 2,...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/90 - 10/31/90

The goal of this Phase I research is to design, synthesize, develop, and evaluate the in vitro efficacy of a new class of polymeric "targeted" prodrugs of AZT. The overall objective of this program is to create new anti-AIDS prodrugs which will possess markedly enhanced antiviral activity, low toxicity, target-accessibility, and sustained drug ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/87 - 04/30/88

The objective of this project is to improve the selectivity of action on platinum antitumor agents. Platinum compounds have shown activity in many types of tumors but severe dose-limiting side effects have affected their clinical utility. By directing these agents more specifically to tumor sites, their effectiveness should be improved. The a...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 01/01/87 - 09/30/87

Synthetic elastase inhibitors for use in the treatment of emphysema will be developed. In Phase I, new mechanism-based elastase inhibitors will be synthesized, characterized and then studied as inhibitors of elastase in vitro. These inhibition studies will analyze both the reversible behavior of the inhibitors, as well as time dependent, irrev...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/86 - 05/30/87

The complex 4-carboxyphthalato(1,2-diaminocyclohexane)platinum (NSC 271674; DACH-Pt) invented by one of the proposed INvestigators, has undergone limited clinical trials at Memorial Sloan-Kettering Cancer Center, New York. Designed as an alternative therapy to cisplatin, it has demonstrated substantially reduced toxicity and enhanced activity i...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/86 - 06/30/87

The overall objective of ongoing research is to develop as a new marketable pharmaceutical product, a platinum based antitumor agent which would have significant advantages over the commercially very successful drug, cisplatin. Advantages sought include but are not limited to overcoming the dose limiting nephro- and gastrointestinal toxicities ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/85 - 03/31/86

The overall objective of ongoing research is to develop as a new marketable pharmaceutical product, a platinum based antitumor agent which would have significant advantages over the commercially very successful drug, cisplatin. Advantages sought include but are not limited to overcoming the dose limiting nephro- and gastrointestinal toxicities ...

Phase 2 SBIR

Agency: Air Force
Topic: AF83-11C
Budget: 01/01/84 - 12/31/84

FLUOROALKYLARYLENESILOXANE (FASIL) POLYMERS POSSESS EXCELLENT THERMAL STABILITY, LOW TEMPERATURE ELASTICITY, AND HYDROCARBON RESISTANCE. POLYMERS BASED ON FASIL HAVE EXTENSIVE PROMISE FOR MILITARY AND COMMERCIAL AEROSPACE APPLICATIONS, IF THE DESIGNED PROPERTIES OF THE ELASTOMERS COULD BE ACHEIVED. IN PHASE I STUDIES, METHODS WERE DEVELOPED FOR...

Phase 1 SBIR

Agency: Air Force
Topic: AF83-11C
Budget: 01/01/83 - 12/31/83